Our areas of interest
Since 2009 we’ve had more new medicines approved than any other healthcare company, including treatments for asthma and COPD, HIV and cancer. And we have many potential new medicines and vaccines in development.
Scientific innovation is also critical to our consumer healthcare business. It helps us differentiate our products and keep pace with changes in the market and consumers’ needs.
Our continued success depends on our relentless drive to innovate and to widen access to our medicines, vaccines and consumer healthcare products, especially in hard-to-reach areas of the world.
The length of time and costs involved in drug discovery and development make it essential that we are highly selective about where we invest our resources. Our current key areas of interest are:
- HIV and infectious diseases
- Rare diseases
We are also committed to finding solutions for difficult-to-treat and neglected diseases, with programmes to find new antibiotics and treatments for cancer, dementia and neglected tropical diseases.
A key part of our approach in vaccines R&D is expanding our access to new vaccine technologies and solutions.
Our aim is to identify and develop vaccines that can help the body raise an immune response against an infective organism or - with our newer stage research - diseased cells. With today’s challenges in vaccinology we frequently work in partnership to develop the vaccines of the future.
The focus in our consumer business is on creating a continual pipeline of new, scientiﬁcally differentiated products which deﬁne our four Consumer Healthcare categories: Oral Health, Skin Health, Nutrition and Wellness.
Through new technologies and formulations we provide products that meet the needs of consumers and are valued by experts, particularly in areas such as sensitive teeth, family nutrition and smoking cessation.
You can find out more about our consumer healthcare research on our Open Innovation website.